JP2022515652A5 - - Google Patents

Info

Publication number
JP2022515652A5
JP2022515652A5 JP2021538213A JP2021538213A JP2022515652A5 JP 2022515652 A5 JP2022515652 A5 JP 2022515652A5 JP 2021538213 A JP2021538213 A JP 2021538213A JP 2021538213 A JP2021538213 A JP 2021538213A JP 2022515652 A5 JP2022515652 A5 JP 2022515652A5
Authority
JP
Japan
Prior art keywords
composition according
compound
subject
group
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021538213A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022515652A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/069057 external-priority patent/WO2020142485A1/en
Publication of JP2022515652A publication Critical patent/JP2022515652A/ja
Publication of JP2022515652A5 publication Critical patent/JP2022515652A5/ja
Pending legal-status Critical Current

Links

JP2021538213A 2018-12-31 2019-12-31 キナーゼ阻害剤化合物及び組成物ならびに使用方法 Pending JP2022515652A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862786966P 2018-12-31 2018-12-31
US62/786,966 2018-12-31
PCT/US2019/069057 WO2020142485A1 (en) 2018-12-31 2019-12-31 Kinase inhibitor compounds and compositions and methods of use

Publications (2)

Publication Number Publication Date
JP2022515652A JP2022515652A (ja) 2022-02-21
JP2022515652A5 true JP2022515652A5 (cg-RX-API-DMAC10.html) 2023-01-11

Family

ID=71407428

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021538213A Pending JP2022515652A (ja) 2018-12-31 2019-12-31 キナーゼ阻害剤化合物及び組成物ならびに使用方法

Country Status (7)

Country Link
US (1) US20220162182A1 (cg-RX-API-DMAC10.html)
EP (1) EP3906233B1 (cg-RX-API-DMAC10.html)
JP (1) JP2022515652A (cg-RX-API-DMAC10.html)
CN (1) CN113508111A (cg-RX-API-DMAC10.html)
AU (1) AU2019419414A1 (cg-RX-API-DMAC10.html)
CA (1) CA3124700A1 (cg-RX-API-DMAC10.html)
WO (1) WO2020142485A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019100062A1 (en) 2017-11-20 2019-05-23 Ichan School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
JP2021510153A (ja) 2018-01-05 2021-04-15 アイカーン スクール オブ メディシン アット マウント サイナイ 膵臓ベータ細胞の増殖を増加させる方法、治療方法、および組成物
ES3038913T3 (en) 2018-03-20 2025-10-15 Icahn School Med Mount Sinai Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes
US20250236613A1 (en) * 2021-10-25 2025-07-24 Sironax Ltd. Sarm1 modulators, preparations, and uses thereof

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2053549T3 (es) 1986-08-11 1994-08-01 Innovata Biomed Ltd Un proceso para la preparacion de una formulacion farmaceutica apropiada para inhalacion.
US5179079A (en) 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
GB8723846D0 (en) 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US4994439A (en) 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
EP0460064A4 (en) 1989-02-23 1992-04-01 Rorer International (Holdings) Inc. Therapeutic aerosol formulations
GB8921222D0 (en) 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
US5731424A (en) 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US5731144A (en) 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands
US5230884A (en) 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5292499A (en) 1990-09-11 1994-03-08 University Of Wales College Of Cardiff Method of preparing medical aerosol formulations including drug dissolved in reverse micelles
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
CH689139A5 (de) 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US5635161A (en) 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
US6120794A (en) 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
ATE243998T1 (de) 1995-10-12 2003-07-15 Supergen Inc Liposomformulierung von 5-beta steroiden
AU744939B2 (en) * 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
US6806358B1 (en) 1997-12-16 2004-10-19 University Of California San Diego Peptide inhibitor of TGF-β growth factors
AU760046B2 (en) 1998-02-27 2003-05-08 United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Disubstituted lavendustin a analogs and pharmaceutical compositions comprising the analogs
GB9809869D0 (en) 1998-05-09 1998-07-08 Medical Res Council Inhibition of protein kinases
JP2002535242A (ja) 1998-05-20 2002-10-22 ザ リポソーム カンパニー、インコーポレーテッド 新規な粒子状剤型
GB9814172D0 (en) 1998-06-30 1998-08-26 Andaris Ltd Formulation for inhalation
US6451349B1 (en) 1998-08-19 2002-09-17 Quadrant Healthcare (Uk) Limited Spray-drying process for the preparation of microparticles
AUPP494798A0 (en) 1998-07-29 1998-08-20 Pacific Biolink Pty Limited Protective protein formulation
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US6290987B1 (en) 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
ES2146552B1 (es) 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
EP1338272A1 (en) 1998-12-21 2003-08-27 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application comprising chenodeoxycholate or deoxycholate
US6436367B1 (en) 1998-12-21 2002-08-20 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application
US6294153B1 (en) 1998-12-21 2001-09-25 Generex Pharmaceuticals, Inc. Aerosol pharmaceutical formulation for pulmonary and nasal delivery
AU2879100A (en) 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
AU3957400A (en) 1999-04-16 2000-11-02 Novo Nordisk A/S Dry, mouldable drug formulation
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
AU5936400A (en) 1999-06-04 2000-12-28 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
US20010036481A1 (en) 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
CA2382821A1 (en) 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
BR0107764A (pt) 2000-01-20 2002-11-12 Basilea Pharmaceutica Ag Composições de peptìdeo cìclico nasalmente administráveis
EP1129705A1 (en) 2000-02-17 2001-09-05 Rijksuniversiteit te Groningen Powder formulation for inhalation
JP2004500424A (ja) 2000-04-17 2004-01-08 ヴェクトゥラ リミテッド 吸入器で使用するための製剤
GB0009468D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
US20020155084A1 (en) 2000-06-02 2002-10-24 The Regents Of The University Of The Michigan Nanoemulsion formulations
US6509318B1 (en) 2000-09-29 2003-01-21 The Regents Of The University Of California TGF-B inhibitors and methods
FI20002768L (fi) 2000-12-18 2002-06-19 Licentia Oy Enteropäällysteisiä lääkekoostumuksia ja niiden valmistus
US20030134836A1 (en) * 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
GB0107106D0 (en) 2001-03-21 2001-05-09 Boehringer Ingelheim Pharma Powder inhaler formulations
SI1397364T1 (sl) 2001-05-24 2007-12-31 Lilly Co Eli Novi pirolni derivati kot farmacevtske uäśinkovine
US20030019437A1 (en) 2001-07-26 2003-01-30 John Fore Ungulate game animal feed system and method
US20030028905A1 (en) 2001-07-31 2003-02-06 Petra Knaus Mutant forms of the TGF-beta type II receptor which bind all TGF-beta isoforms
US20030064033A1 (en) 2001-08-16 2003-04-03 Brown Larry R. Propellant-based microparticle formulations
WO2003072080A1 (en) 2002-02-22 2003-09-04 Advanced Inhalation Research, Inc. Inhalable formulations for sustained release
CA2478974C (en) 2002-03-20 2014-12-16 Advanced Inhalation Research, Inc. Inhalable sustained therapeutic formulations
DE60307082D1 (de) 2002-05-07 2006-09-07 Ferring Bv In der mundhöhle dispergierbare phamarzeutische zusammensetzung mit desmopressin
JP2005530800A (ja) 2002-05-15 2005-10-13 スミスクライン・ビーチャム・コーポレイション ベンゾオキサジンおよびベンゾオキサジノン置換トリアゾール
AU2003229305A1 (en) 2002-05-17 2003-12-02 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS
US7190468B2 (en) 2002-07-17 2007-03-13 Hewlett-Packard Development Company, L.P. Background document rendering system and method
EP1539748A1 (en) 2002-07-31 2005-06-15 Smithkline Beecham Corporation 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
WO2004026871A1 (en) 2002-09-17 2004-04-01 Eli Lilly And Company Novel pyrazolopyridine derivatves as pharmaceutical agents
KR20050057441A (ko) 2002-09-18 2005-06-16 화이자 프로덕츠 인코포레이티드 전환 성장 인자 억제제로서의 신규한 아이소티아졸 및아이속사졸 화합물
JP2006502236A (ja) 2002-09-18 2006-01-19 ファイザー・プロダクツ・インク 形質転換成長因子(tgf)阻害剤としてのトリアゾール誘導体
WO2004047818A2 (en) 2002-11-22 2004-06-10 Scios, Inc. USE OF TFG-β INHIBITORSTO COUNTERACT PATHOLOGIC CHANGES IN THE LEVEL OR FUNCTION OF STEROID/THYROID RECEPTORS
JP4896518B2 (ja) * 2002-12-13 2012-03-14 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド ニコチンアミド系キナーゼ阻害薬
JP2006516603A (ja) 2003-01-27 2006-07-06 ファイザー・プロダクツ・インク イソチアゾール誘導体
DE602004014347D1 (de) 2003-03-12 2008-07-24 Millennium Pharm Inc Chinazolin-derivate als tgf-beta-inhibitoren
EP1608631A4 (en) 2003-03-28 2008-08-20 Scios Inc BICYCLIC PYRIMIDININHIBITORS OF TGF BETA
ES2389258T3 (es) 2003-06-17 2012-10-24 Millennium Pharmaceuticals, Inc. Composiciones y métodos para inhibir TGF-s
EP1644365A2 (en) * 2003-07-02 2006-04-12 Biofocus Discovery Ltd Pyrazine and pyridine derivatives as rho kinase inhibitors
JP4688680B2 (ja) 2003-10-28 2011-05-25 独立行政法人理化学研究所 TGF−β情報伝達経路阻害剤
CA2551524A1 (en) 2003-12-24 2005-07-21 Scios, Inc. Treatment of malignant gliomas with tgf-beta inhibitors
US7368445B2 (en) 2004-03-01 2008-05-06 Eli Lilly And Company Fused pyrazole derivatives as TGF-β signal transduction inhibitors for the treatment of fibrosis and neoplasms
US20090196912A1 (en) * 2004-07-30 2009-08-06 Gpc Botech Ag Pyridinylamines
JP2007176795A (ja) 2004-08-18 2007-07-12 Univ Nihon TGF−β遺伝子発現抑制剤
CN101189234B (zh) 2005-03-25 2011-08-17 泰博特克药品有限公司 Hcv的杂二环抑制剂
CA2616196C (en) 2005-07-22 2012-08-21 Eli Lilly And Company A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor
AU2005337776B2 (en) 2005-10-24 2013-01-31 Proyecto De Biomedicina Cima, S.L. Use of TGF-Beta1 inhibitor peptides in the preparation of an immune response modulating agent
WO2007084667A2 (en) * 2006-01-19 2007-07-26 Osi Pharmaceutical, Inc. Fused heterobicyclic kinase inhibitors
ITMI20060181A1 (it) 2006-02-03 2007-08-04 Univ Padova Modulatori del tgf-b e loro uso
BRPI0807961A2 (pt) * 2007-02-13 2017-05-16 Pharmacopeia Llc agonista de alfa2c adrenorreceptor funcionalmente seletivos.
EP2197876A1 (en) 2007-08-29 2010-06-23 Glaxosmithkline LLC Thiazole and oxazole kinase inhibitors
US8298825B1 (en) 2008-08-25 2012-10-30 The General Hospital Corporation TGF-beta receptor inhibitors to enhance direct reprogramming
GB0821307D0 (en) * 2008-11-21 2008-12-31 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
AU2010247412A1 (en) * 2009-05-15 2011-11-24 Novartis Ag 5-pyridin-3-yl-1,3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1
EP2763976B1 (en) * 2011-10-05 2016-05-18 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
WO2014018691A1 (en) 2012-07-24 2014-01-30 The Trustees Of Columbia University In The City Of New York Generation of airway and lung progenitors and epithelial cells and three-dimensional anterior foregut spheres
CN105142621A (zh) * 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
MX2015007097A (es) * 2012-12-10 2015-09-29 Hoffmann La Roche Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer.
GB2519623A (en) * 2013-06-18 2015-04-29 4Sc Discovery Gmbh Method of inhibiting DYRK1B
US9725463B2 (en) * 2013-06-21 2017-08-08 Lupin Limited Substituted heterocyclic compounds as CRAC modulators
US20170280720A1 (en) * 2014-09-17 2017-10-05 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
KR20170141767A (ko) * 2015-04-29 2017-12-26 얀센 파마슈티카 엔.브이. 벤즈이미다졸론 및 벤조티아졸론 화합물 및 ampa 수용체 조절제로서의 이들의 용도
WO2017008694A1 (zh) 2015-07-11 2017-01-19 常州合力电器有限公司 直流松土机
US11332716B2 (en) * 2015-07-27 2022-05-17 The Regents Of The University Of California Methods and compositions for producing pancreatic beta cells
AU2016315881B2 (en) * 2015-09-03 2019-09-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK1A and uses thereof
EP3389720A1 (en) * 2015-12-18 2018-10-24 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
US10487087B2 (en) 2015-12-30 2019-11-26 Vanderbilt University Positive allosteric modulators of the GLP-1 receptor
JP6596390B2 (ja) 2016-06-29 2019-10-23 株式会社沖データ 現像剤収容器、現像装置、画像形成装置、及び基板支持構造

Similar Documents

Publication Publication Date Title
JP2022515650A5 (cg-RX-API-DMAC10.html)
JP2021518413A5 (cg-RX-API-DMAC10.html)
JP6936823B2 (ja) 抗癌活性及び抗増殖活性を呈する2−アミノピリミジン−6−オン及び類似体
US10383881B2 (en) 1,5-dihydro-2H-pyrrol-2-one compounds and methods of using same
RU2627712C2 (ru) Соединение как ингибитор передачи сигналов wnt, его композиции и применение
US11066419B2 (en) 1H-pyrrole-2,5-dione compounds and methods of using same
US9744169B2 (en) Compounds for treatment of fibrosis diseases
RU2008142360A (ru) Производные амидов и их применение для лечения нарушений, связанных с белком g
US20150238601A1 (en) Treatment of ocular disorders
CA2942753A1 (en) Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
JP2017061464A (ja) がん治療のための方法として低酸素誘導因子−2αを安定化するための、化合物および組成物
JP2021518413A (ja) キナーゼ阻害剤化合物及び組成物ならびに使用方法
AU2023201216A1 (en) Methods for controlled proliferation of vestibular stem cells / generating inner ear hair cells using wnt and tgf-beta inhibition
JP2010505797A (ja) Hcv阻害剤として有用なカルボキシアミド4−[(4−ピリジル)アミノ]ピリミジン
WO2021263129A1 (en) Kinase inhibitor compounds and compositions and methods of use
AU2018204290A1 (en) Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
US20240245682A1 (en) Alpha-v-beta-8 integrin inhibitors and uses thereof
CN113508111A (zh) 激酶抑制剂化合物和组合物及使用方法
JP2021503486A5 (cg-RX-API-DMAC10.html)
JP2025513877A5 (cg-RX-API-DMAC10.html)
JP7725076B2 (ja) グルコシルセラミド合成酵素のピリジン阻害剤及びそれらを使用する治療方法
JP7041877B2 (ja) チエノ[2,3-b]ピリジン誘導体およびキノリン誘導体ならびにそれらの使用
EP2871181B1 (en) Novel Compounds for Regeneration of Terminally-Differentiated Cells and tissues
US20200316089A1 (en) 1,2-dihydro-3h-pyrazol-3-one compounds and methods of using same
KR20210135279A (ko) 신경퇴행성 질환 및 암 치료용 화합물